NovoCure Limited (NVCR) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the NovaCure fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I'd now like to hand the conference over to Adam Dainey, Head of Investor Relations. Please go ahead. Good morning, and thank you for joining us to review Novacure's fourth quarter and full year 2025 performance. I'm joined on the phone today with our Executive Chairman Bill Doyle, CEO Frank Leonard, and CFO Christophe Brockman. Other members of our executive leadership team will be available for Q&A. For your reference, Slides accompanying this earnings release can be found on our website at www.novacure.com on the Investor Relations page under Quarterly Reports. Before we start, I would like to remind you that our discussions today during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted...